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THE LINC  COMES  HOME 
In the early 1960s, digital computers were massive 
and expensive. Far biomedical researchers, the 
computers were neither accessible nor compatible 
with their scientific needs. A group at Massachusetts 
Institute of Technology's (MIT's) Lincoln Laboratory 
set out to build an all-purpose, inexpensive, research- 
friendly module. The National Institutes of Health 
(NIH) recognized MIT's design as an important 
research tool and encouraged research teams nation- 
wide to submit proposals for projects to evaluate the 
Laboratory Instrument Computer (LINC, as MIT's 
design was called) as a lab tool. In all, 12 grants— 
which included funds to build a LINC—were awarded; 
Washington University in St. Louis was among 
the recipients. 
Eventually, as technology evolved and computers 
became smaller, faster, and less expensive, LINCs 
were phased out, often relegated to the trash heap. 
Of the 50 LINC machines eventually built, only a 
handful survived—and one of them is being restored 
and will be permanently displayed at the Washington 
University Medical Center. 
Photographs by Kimberly Kania. 
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IJ Mallinckrodt Institute 
'"adiology 
Visit the MIR web site at 
www.mir.wustl.edu 
4 Let there be...bioluminescence 
Scientists in the Molecular Imaging 
Center have a new way to identify 
cell inflammation before a tumor 
forms—that old crime-scene 
standby, luminal, and its reaction 
to an immune system bleach. 
8 Unlocking the secrets of 
Alzheimer's disease 
Nuclear medicine physicians are 
using positron emission tomogra- 
phy in several collaborative studies 
to detect Alzheimer's disease before 
the onset of cognitive symptoms. 
14 Imaging the behavior of 
cancer cells 
Researchers in MIR's Radiological 
Chemistry Lab have developed a 
new approach—positron emission 
tomography and sigma-2 receptors— 
to directly visualize the behavior of 
cancer cells. 
18 CRMO—imaging is key to 
accurate diagnosis 
Multimodality imaging is helping to 
diagnose and assess chronic recur- 
rent multifocal osteomyelitis, an 
autoinflammatory disease affecting 
children and young adults. 
A paradoxical view of cancer 
Collaborative research has made a 
marked contribution to the cure of 
advanced breast cancer—a novel 
way of assessing the best treatment 
for patients who have exhausted 
most available therapies. 
ON THE COVER Robert Much, PhD, is in the Insti- 
tute's cyclotron facility, where radiotracers are pro- 
duced for use in PET imaging of solid tumor cell 
proliferation. Photograph by Tim Parker. 
>TNEWS 
WUSM among nation's 
top schools 
I, WORLD REPORT 
H:|lI:iV»:ni-7l7| ti^Mte 
In the 2009 U.S. News & World Report rankings 
of graduate and professional programs, Washington University School of Medicine was named 
third among the country's top 10 research-oriented medical schools—tied with the University of 
Pennsylvania. The top spot went to Harvard University, second to Johns Hopkins University. The 
University of California, San Francisco was ranked fifth, with Duke University, Stanford Univer- 
sity, the University of Washington, and Yale University tied for sixth place. For the eleventh con- 
secutive year, WUSM was named number one in student selectivity (based on college grade-point 
averages and MCAT scores). 
Bhalla lecture 
Sanjeev Bhalla, MD, associate professor of radiology and chief of Cardiothoracic 
Imaging, was selected by the Washington University School of Medicine students as the 
56"' Annual Alpha Omega Alpha lecturer. He holds the honor of being one of two faculty 
members to have been selected twice as lecturer. Bhalla presented "Lights along the path: 
getting the most education in residency." 
The Alpha Omega Alpha Honor Society, established 107 years ago at the College of 
Physicians and Surgeons in Chicago, is considered the most prestigious honor society in 
the medical profession and has more than 50,000 members nationally. The Washington 





ton University's 148°' 
Commencement ceremony 
in May, Lauren Qing 
Chang Sen received the 
2009 Hugh M. Wilson 
Award for Meritorious 
Work in Radiology. Sen, 
a fourth-year medical stu- 
dent, was mentored by 
Jay Heiken, MD, professor 
of radiology and chief of 
Abdominal Imaging. The 
annual Wilson Award 
honors Mallinckrodt 
Institute's second director, 
an advocate of the 
advancement of education. 
9 fy Alpha  Omega 
Worthy to Serve the Suffering 
Honor Medica 
founded  1 902 
CMS expands coverage for PET 
The Centers for 
Medicare & Medicaid 
Services (CMS) announced 
in April that it would cover 
costs for positron emission 
tomography (PET) scans 
used to support initial diag- 
nosis and treatment for most 
solid tumor cancers. CMS 
also expanded coverage for 
the use of PET scans for 
follow-up testing for cervical 
and ovarian cancer and 
myeloma. Eight other types 
of cancer continue to be 
covered: breast, colorectal, 
esophageal, head and neck, 
lymphoma, melanoma, non- 
small cell lung, and thyroid. 
Follow-up testing of all other 
cancers continues under the 
CMS coverage with evidence 
development (CED) policy. 
The CMS decision was 
fueled by clinical results of 
the NOPR (National Onco- 
logic PET Registry) study, 
a nationwide CED effort 
that helped to prove the 
effectiveness of PET in diag- 
nosing, staging, restaging, 
and monitoring treatment 
for many cancers. Sponsored 
by the Academy of Molecular 
Imaging and managed by 
the American College of 
Radiology (ACR) and the 
ACR Imaging Network, the 
NOPR began accruing 
patients in May 2006. 
Mallinckrodt Institute's Bar' 
Siegel, MD, a key advocate 
for and organizer of the 
NOPR, serves as cochair of 
the NOPR working group. 
To read more about this 
expanded coverage, go to 
www.cms.hhs.gov. In the 
search box, type "PET 
coverage for cancer." 
MALLINCKRODT INSTITUTE OF RADIOLOGY 
Street earns RSNA R&E award 
Mandie Street, AERT, 
clinical research coordinator, 
received a Radiological Soci- 
ety of North America (RSNA) 
Research and Education 
Foundation award for her 
project "Using six sigma 
techniques to reduce radia- 
tion dose," which will assess 
progress in optimizing radia- 
tion exposure during pedatric 
fluoroscopy procedures. The 
award of up to $10,000 is 
sponsored by the Association 
of University Radiologists, 
the Association of Program 
Directors in Radiology, and 
the Society of Chairmen of 
Academic Radiology Depart- 
ments. James Duncan, MD, 
PhD, associate professor of 
radiology, serves as Street's 
mentor for the project. 
I 
I 
Welch corecipient of cancer fund grant 
Michael Welch, PhD, professor of radiology, of chemistry, and of molecular 
biology and pharmacology, and John-Stephen Taylor, PhD, professor of chemistry, 
received the first research grant awarded by the Kay Yow/Women's Basketball 
Coaches Association (WBCA) Cancer Fund and the V Foundation for Cancer 
Research. The 
$100,000 award will 




ticles optimized for 
breast cancer diag- 
nosis and therapy." 
The award was 
presented during 
the NCAA Women's 
Final Four week- 





coach and breast 
cancer patient who 
died recently, cre- 
ated the Kay Yow/ 
WBCA Cancer 
Fund in 2007 to 
(left to right) Michael Welch, PhD; Sue Donohoe, vice president, NCAA Division 1 
Women's Basketball; John-Stephen Taylor, PhD; Marsha Sharp, president, Kay Yow/ 
WBCA Cancer Fund; Nick Valvano, CEO, the V Foundation. Photo by Ray Marklin. 
fund research of women's cancers and to assist underserved women. The V Founda- 
tion for Cancer Research was established in 1993 by ESPN and the late Jim Valvano, 
North Carolina State University basketball coach and ESPN commentator. 
Faculty receive 
honors 
Maurizio Corbetta, MD, 
professor of neurology, of 
radiology, and of anatomy 
and neurobiology, was one 
of five recipients of the 
Washington University 
School of Medicine Distin- 
guished Investigator Award. 
The award is among the 
Distinguished Faculty 
Awards presented annually 
to recognize outstanding 
achievements in clinical 
care, community service, 
research, and teaching. 
Emily Smith, MD, assis- 
tant professor of radiology, 
was one of two honorees 
who received the WUSM 
Alumni/Faculty award. She 
earned a WUSM medical 
degree in 1968 and completed 
a diagnostic radiology resi- 
dency in 1972. In addition to 
serving on the Mallinckrodt 
Institute faculty for the past 
35 years, Smith is an Eliot 
Society Patron and has 
chaired the WUSM Annual 
Fund for 11 years. 
Pamela Woodard, MD, 
associate professor of radiol- 
ogy and cohead of Cardiac 
CT/MR, was elected a fellow 
of the American College of 
Radiology (ACR), one of the 
highest honors ACR can 
bestow on a radiologist, 
radiation oncologist, or 
medical physicist. The con- 
vocation ceremony was in 
May at the ACR's 86th 
Annual Meeting and Chapter 
Leadership Conference. 
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by Robert Lowes 
I 
> 
On summer nights, 
• children chase after fireflies, trying to capture these fascinating 
insects that generate their own blinks of light. 
Then there's David Piwnica-Worms, MD, PhD, professor of 
, radiology and of developmental biology. He exploits firefly-like 
chemistry to capture glowing images of disease in living mice. 
What he's seen lately on his computer screen leaves him as 
astonished as a child. 
A molecule called luminol—cousin to light-producing luciferin 
in fireflies—shines blue when it reacts with an immune-system 
bleach that causes tissue inflammation. Using this type of 
bioluminescence, Piwnica-Worms and his research team have 
spotted the subtlest beginnings of inflammation in the tail of a 
mouse—not detectable by sight or palpation—only to watch it 
morph into a tumor four weeks later. "We were amazed that we 
could show inflammation starting long before the tumor formed," 
says Piwnica-Worms, director of the Molecular Imaging Center 
(MIC) at Washington University. 
, 
His team published its findings 
on bioluminescence imaging of 
inflammation earlier this year in 
the journal Nature Medicine. It 
marked the latest development in a 
molecular imaging technique that 
Piwnica-Worms has honed over the 
past 10 years, a technique that in 
some applications could someday 
outshine such stalwarts as mag- 
netic resonance imaging (MRI). 
With every new finding, Piwnica- 
Worms demonstrates the versatility 
of bioluminescence imaging, which 
is already helping to develop new 
drugs and may someday spot 
potential blood clots and even 
guide the hand of cancer surgeons. 
When bleach is spilled 
Piwnica-Worms has literally 
taken his scientific cues from the 
humble firefly. In earlier research 
projects, he and his team extracted 
the firefly gene that makes an 
enzyme called luciferase and intro- 
duced it into lab mice, often in the 
role of a "reporter" gene. They 
once added the gene to the DNA of 
a strain of mice so the animals could 
make their own luciferase. The mice 
were then injected with a common 
cold virus that was genetically 
engineered to turn on the luciferase 
gene. The mice also received a dose 
of luciferin, a firefly compound 
that glows when it encounters 
luciferase. When investigators put 
the live mice under a special 
camera in a light-free box, they 
could identify tissues infected by 
the virus, since it triggered the 
production of luciferase wherever 
it spread, and the luciferase, in 
turn, reacted with the luciferin. 
MIC researchers have used this 
luciferase-luciferin combo in other 
ways to illuminate gene expression 
and protein function in disease 
processes. As a result, they've 
learned how to use this form of 
bioluminescence to screen various 
compounds for drug candidates 
and to test the efficacy of experi- 
mental drugs in mice. 
The experiment 
described in Nature 
Medicine achieved 
bioluminescence 
with luminol, a 
man-made version 
of luciferin. It's the 
ingredient that 
makes glow sticks 
glow, but luminal is 
put to a gruesome 
task in law enforce- 
ment. Because it 
reacts with blood to 
produce a blue 
light, detectives 
routinely spray 
crime scenes with a 
solution containing 
luminol and hydro- 
gen peroxide to 





turned to luminol 
as well, in part 
because it appears 
to be safe to use in human experi- 
ments, although further research is 
needed to bear that out. 
The focus of the Nature Medicine 
study was myeloperoxidase, or MPO, 
a key protein found in two immune 
cells called neutrophils and 
macrophages. Such cells are pro- 
grammed to swallow an intruder 
such as a bacterium, enclose it in 
a sack-like structure called a phago- 
some, and inject the phagosome 
with MPO and hydrogen peroxide. 
The MPO then produces hypochlor- 
ous acid to destroy the cocooned 
invader. "Hypochlorous acid is basi- 
cally a type of bleach, and bleach is 
a great antiseptic," says Piwnica- 
Worms, the study's senior author. 
The bleach helps mice as well 
as humans stave off bodily insults, 
but during an autoimmune 
response, it doesn't necessarily 
stay confined to the phagosomes 
Robin Dothager, PhD, post doctoral research associate, and (le(t) David Piwnica- 
Worms, MD, PhD, are in the bioluminescence imaging room. The black box takes 
images of photons emitted by mice; that data is then fed into computers for analysis. 
and that's what contributes to 
inflammation at its destructive 
worst. " You have a big battle that 
gets out of control," says Piwnica- 
Worms. "The neutrophils and 
macrophages are spilling bleach on 
the body's own tissues." 
MPO catalyzes other loose 
cannon molecules such as tyrosyl 
radicals that damage invader and 
host alike. This havoc isn't good, 
because inflammation is a precur- 
sor to a wide variety of disorders 
linked to the immune system— 
rheumatoid arthritis, atherosclerosis, 
renal glomerular injury, pulmonary 
fibrosis, Alzheimer's disease, 
Parkinson's disease, and certain 
cancers. So analyzing the bleach 
production of MPO has enormous 
potential for studying and treating 
these diseases. 
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bioluminescence 
Earlier studies at other 
research centers have observed 
luminal-bioluminescence in 
MPO-produced hypochlorous 
acid in test tube experiments and 
extracted whole blood. Shimon 
Gross, PhD, lead author of the 
Nature Medicine article and a 
former post-doctoral fellow in 
the MIC, wanted to see if luminol 
would shine when it penetrated 
the phagosomes of immune cells 
in living animals and reacted with 
bleach there. Enter the lab mice. 
"Gene-knockout" mice prove 
a point 
The luminol experiment involved 
two sets of mice. One set was nor- 
mal, as mice go. The other group 
was genetically engineered so that 
the gene responsible for creating 
MPO was turned off. In other 
words, neutrophils and macrophages 
in these "gene-knockout" mice 
couldn't manufacture hypochlorous 
acid. Thus, if MPO was the primary 
source of the observed biolumines- 
cence, then the MPO gene-knock-out 
mice should not glow. 
Both sets of mice had the same 
disorders involving inflammation. 
Some had dermatitis, others had 
arthritic ankles. Still others were 
genetically engineered so they 
were prone to develop tumors, 
often at the site of a bite or scratch. 
MIC researchers took biolumines- 
cent snapshots of them on a daily 
or weekly basis, depending on the 
disorder. Each imaging session was 
preceded by a luminol injection. 
Piwnica-Worms was gratified 
to see the blue glow of scientific 
confirmation. Bioluminescence 
imaging detected inflammation in 
normal mice, but not in those lacking 
MPO. What caused the biolumines- 
cence in particular was the highly 
concentrated bleach inside the 
phagosomes of immune cells. In 
contrast, hardly any bioluminescence 
materialized in conjunction with 
Kelly Flentie, graduate research assistant, and 
Piwnica-Worms in the Cell Biology Lab. 
eosinophil peroxidase, or EPO, a 
protein similar to MPO that's found 
in immune cells called eosinophils. 
EPO creates its own weapon— 
hypobromous acid—to destroy 
microscopic trespassers, and while 
this acid makes luminol glow in a 
test tube, it didn't do that in vivo in 
the MIC experiment. Because 
eosinophils squirt their acid at for- 
eign bodies without first engulfing 
them, "the relative concentration 
of the reactants is too low to elicit 
significant bioluminescence," 
notes Gross. 
Vivo in vivo 
The MIC research on luminol- 
bioluminescence underlines the 
value of diagnostic imaging that 
can monitor the course of disease 
in vivo and noninvasively over 
weeks and months. That doesn't 
happen with traditional ex vivo 
research techniques, explains 
Piwnica-Worms. "You'd sacrifice a 
mouse to study inflammation in a 
tissue sample, for example, but 
you'd never know whether that 
inflammation would lead to cancer 
two months later." 
By eliminating the need to 
continually sacrifice lab mice, in 
vivo imaging allows investigators 
to use fewer of them, reducing 
costs. In addition, statistical results 
are tighter, he says. "Each mouse 
is compared to itself over time." 
Other imaging techniques can 
monitor diseases processes in vivo, 
but luminol-bioluminescence out- 
performs them in several respects. 
One advantage is greater sensitivity 
to low-level inflammation as mea- 
sured by signal-to-noise ratio. In 
bioluminescence images of one 
type of tissue inflammation 
described in the Nature Medicine 
study, this ratio exceeded 3000. 
x1 
MALLINCKRODT INSTITUTE OF RADIOLOGY 
Shimon Gross, PhD 
! 
When MRI and single photon 
emission computed tomography 
(SPECT, a nuclear medicine imagng 
technique based on gamma rays) 
were used, it 
dropped to 1.7 and 
2.6, respectively. 
Due to its relative 
simplicity, luminol- 
bioluminescence 
imaging also is a 
speedier way to 
obtain biological 
images. "We can 
process two 
hundred mice in a 
single afternoon to 
fully characterize a 
biochemical or drug 
action," says 
Piwnica-Worms. "We are fans of 
all modalities, but MRI and PET 
[positron emission tomography] 
are limited by their throughput 
rate. It's a great day if we get four 
mice done." 
Luminol-bioluminescence 
imaging, as it stands now, has one 
significant disadvantage that would 
hamper any future application 
with human 
subjects—it 
can't see very 
deep inside the 
human anatomy. 
The light emit- 
ted by luminol 
can only travel 
up to one cen- 






Imaging arthritis with 
luminol-bioluminescence 
imaging. 
10 photons s 1 
-2     -1 
cm   sr 
Consequently, the technique cur- 
rently would work just for the skin, 
and tissues and blood vessels near 
the surface, such as the carotid 
arteries. In contrast, MRI, SPECT, 
and PET probe the entire body. 
However, Piwnica-Worms says 
it's possible to take biolumines- 
cence imaging deeper by attaching 
the necessary fiber-optic tip to a 
scope. "You could snake the scope 
inside arteries, the colon, or the 
lungs," he says. He's also hoping to 
redesign the luminol molecule so 
that it emits not a blue light, but 
a red one. Due to its longer wave- 
length, a red light could travel two 
or even three centimeters before 
being absorbed by the body. 
No cancer left behind? 
For Piwnica-Worms, a little 
bioluminescence goes a long way. 
Every new discovery invariably 
suggests a dozen more experiments. 
"Sometimes you have more ideas than 
hands to execute them," he jokes. 
The recent findings on MPO 
and inflammation are no exception 
to the rule. He sees numerous pos- 
sibilities for basic bench research. 
"With genetic engineering, 
you could remove the MPO from 
neutrophils but retain it in 
macrophages—or vice versa— 
and study their exact roles in the 
immune system," says Piwnica- 
Worms. "You might be able to 
determine which cell is dominant 
in specific diseases processes." 
Luminol-bioluminescence also 
promises to report on the efficacy 
of experimental drugs—exactly 
when they begin to reduce inflam- 
mation, and what dosages and 
intervals work best. "The technique 
gives us a new metric," he says. 
Someday, clinicians may study 
pictures of lit-up tissue to guide 
treatment of their patients. Take 
plaque buildup in the 
carotid artery, for 
example. "Not all 
plaques are alike," 
says Piwnica-Worms. 
"Some are what we 
call active plaques, 
because they contain 
activated neutrophils 
and macrophages that 
are making bleach. As 
compared to inactive 
plaques, they're more 
likely to become 
thicker, form a 
complete clot, and 
cause a stroke. 
Bioluminescence 
could tell us whether 
a carotid plaque is 
active or not." 
Likewise, luminol- 
bioluminescence may 
eventually help cancer 
surgeons figure out 
where they should 
make an incision 
with their scalpel. 
"Certain cancers 
cause inflammation 
in surrounding tissues," 
says Piwnica-Worms. 
"Bioluminescence 
imaging could help 
physicians to visualize 
the inflammation and get a better 
idea about the tumor's margins. 
They'd be less likely to leave any 
cancer behind." 
All of this, of course, is scientific 
speculation, but Piwnica-Worms 
and his research team have been 
converting speculation about 
bioluminescence imaging into a 
growing body of knowledge. So 
he continues chasing after the 
luminous evidence, out there like 
a cloud of fireflies. EE3 
D through G: large granular 
lymphocytic tumor in mice, 
showing colocalization of 
luminol bioluminescence 
with small tumor ioci 
(yellow arrows). 
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r ELI Alzheimer's 
IMAGING disease 
by Candace O'Connor 
For years, physicians made the official diagnosis of Alzheimer's 
disease (AD) in the pathology laboratory, after a patient had died. 
Imaging methods simply did not work in living patients. While 
high-resolution magnetic resonance imaging (MRI) detected many 
other diseases in the brain, it could not firmly indicate AD. 
"Then something happened that surprised a lot of people," 
says Mark Mintun, MD, professor of radiology and of psychiatry. 
The ability to image amyloid plaques, a hallmark brain lesion of 
AD, dramatically changed that landscape — and PET [positron 
emission tomography] has made that possible." 
Mintun and his team are using PET, combined with exciting 
new radioactive tracers, in a series of studies all focused on one 
aspect of the disease: how to detect AD in its earliest stages before 
cognitive symptoms have become evident. Even then, amyloid 
plaques (the sticky protein deposits that are implicated in the 
development of the disease) have begun to form in the brain, but 
the patient shows no outward signs of illness. 
we could identify 
the pathology of 
Alzheimer's disease 
in someone's brain 
before symptoms 
occur, that would 
mean that we could 
diagnose—and potentially treat— 
the disease before many brain cells 
had died," says Mintun. "Multiple 
treatments are being tested for 
their ability to alter these amyloid 
plaques. But right now, no one gets 
these experimental drugs unless they 
are showing quite a few symptoms." 
In doing this research, Mintun 
and his team are working with a 
number of groups at Washington 
University, especially the Alzheimer's 
Disease Research Center (ADRC), 
internationally renowned for its 
clinical evaluation of patients with 
AD. They also have strong ties to 
basic researchers such as David 
"We hope that PET can 
continue to be a bridge 
between the biochemical 
hypotheses and all the great 
ideas generated in a lab 
such as David Holtzman's, 
and test them in the rigor- 
ous research environment 
of John Morris [professor of 
neurology]," says Mintun. 




Already, scientists know 
that AD, especially at onset, 
progresses very slowly. But 
once it starts, it is implaca- 
ble, killing brain cells and 
eventually causing a host of 
cognitive symptoms such as 
memory loss, poor judgment and 
"We hope that PET can continue to be a bridge 
between the biochemical hypotheses and all the 
great ideas generated in a lab" 
Holtzman, MD, professor of neurol- 
ogy and a world leader in defining 
biochemical changes that charac- 
terize the onset of the disease. 
disorientation. The incidence of AD 
increases rapidly with age, rising to 
some 40 to 50 percent of the 80- 
year-old population. 
Through earlier PET studies, 
researchers also know something 
else: that 25 to 30 percent of people 
aged 70 and older have some amy- 
loid plaques in their brains. But 
researchers don't know whether 
the presence of these plaques 
means that a patient will inevitably 
develop AD. 
Mintun in the PET/CT control room in the Center for 
Clinical Imaging Research. 
"We predict that people with 
amyloid plaques have a higher risk 
of developing Alzheimer's disease, 
and the people without plaques 
have a lower risk," says Mintun. 
"Now we are hoping to see over 
time whether that is true." 
In a 2006 study, published in 
the journal Neurology, Mintun and 
nine colleagues took a first step 
toward making that determination. 
They tested 41 subjects without 
dementia, using PET together with 
an imaging tracer (developed in 
2005 at the University of Pittsburgh) 
called "Pittsburgh Compound-B" or 
"PIB." When it was injected into a 
vein, PIB circulated into the brain, 
sticking to amyloid plaques. 
Researchers could then see the 
plaques on PET scans. 
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PET Alzheimer's 
IMAGING disease 
But that research led to further 
questions: Over time, would these 
plaques continue to develop? More 
importantly, while most patients 
with plaques will likely develop AD, 
is there a subgroup that remains 
free of dementia? 
In new studies, funded primarily 
by the National Institutes of Health 
and by the ADRC, Mintun and others 
are exploring these questions. 
With the ADRC, they are identifying 
more than a hundred subjects aged 
65 and older who show no evidence 
of dementia. Using PIB made in 
Mallinckrodt Institute's Radiolo- 
gical Chemistry Lab, they will scan 
each volunteer annually, and every 
year the ADRC will conduct the 
dementia evaluation. 
Volunteers are not told 
whether they have plaques, and 
since the results are all coded, no 
examining physician knows either. 
"If you were told you have plaques 
that may cause Alzheimer's disease, 
you might start doubting yourself," 
says Mintun. "Am I remembering 
correctly? Maybe I'm losing my 
memory. It's much better if it's 
a blind study." 
Researchers hope to attract as 
many volunteers as possible and 
then to observe them for five to 10 
years, tracking which ones develop 
AD and correlating those findings 
Rows of color images are PET scans of a volunteer who received an injection of Cl 1 -labeled PIB. Shown are horizontal slices of the brain, from the bottom of the brain (left) to 
the top (right). Each PET scan is matched to MRI images (black-and-white rows beneath each colored PET scan) of the same person. Top row: a volunteer with dementia of the 
Alzheimer's type (DAT) has high uptake (indicated by red and yellow) because of binding of the PIB to amyloid plaques. Third row: PET scan of volunteer who is cognitively nor- 
mal has only background levels of PIB in the brain. 
with plaque development. Perhaps 
they will discover, says Mintun, 
that 100 percent of those with 
plaques eventually develop the 
disease. But if 80 percent of those 
with plaques get the disease while 
20 percent do not, that leads to 
other intriguing questions. 
"Do these people have a 
different diet? Are they on some 
medication, maybe for cholesterol? 
Is it because they do crossword 
puzzles or exercise? Is it because 
they don't have diabetes or heart 
disease?"asks Mintun. "What are 
the reasons why someone would 
develop these plaques in the brain 
and yet seem to hold off Alzheimer's 
disease for a long time?" 
More than 20 new treatments 
aimed at clearing these plaques or 
preventing them from developing 
in the first place are currently 
wending their way though clinical 
trials. Not only must pharmaceutical 
companies test the drugs' efficacy, 
but they also have to ensure that 
patients don't experience intolerable 
adverse effects. Still, says Mintun, 
there is strong hope that effective 
new drugs are on the horizon. 
Ideally, he says, physicians 
would like to stop the disease in its 
tracks before— not after—memory 
loss and other symptoms have 
occurred. So this study is of 
immense importance to the future 
treatment of AD. 
"I use the analogy of someone 
who has heart disease, with 
plaques in the coronary arteries," 
says Mintun. "All of a sudden that 
person has a heart attack that 
causes permanent muscle damage; 
at that point, if the plaques are 
removed, it won't reverse the dam- 
age. Amyloid in the brain may be 
In the Radiological Chemistry Lab, Greg Gaehle is 
setting up a carbon-11 PIB synthesis study. 
kicking off a series of events that 
cause the brain cells to die After 
they begin dying, removing the 
amyloid might not be as helpful as 
if you could start the process earlier. 
Looking at the 
hippocampus 
While amyloid plaques 
are one problem in the 
brains of patients with AD, 
researchers are also investi- 
gating whether there are 
others. Mintun is working with 
a Washington University group 
led by Denise Head, PhD, assistant 
professor of psychology, to exam- 
ine the hippocampus, a highly sen- 
sitive part of the brain associated 
with memory and emotions. It 
appears that in patients with AD, 
the hippocampus loses cells and 
begins to shrink as part of the 
disease process. 
"So Doctor Head argued that 
if people with amyloid plaques 
develop the disease so early that 
you can't clinically see it, maybe 
they also had very early loss in the 
hippocampus," says Mintun. "It 
turns out that these patients have 
a normal hippocampus volume, 
but they are in the low end of the 
normal range and significantly dif- 
Hippocampus 
ferent from people lacking plaques. 
Further, their hippocampus volume 
is going down every year." 
This downward trend tallies 
with the results of cognitive testing 
done by Martha Storandt, PhD, pro- 
fessor of psychology, on patients 
who are amyloid-positive and those 
who are amyloid-negative, as iden- 
tified through +PIB/PET. Among 
those who are PIB-positive, their 
cognition—though still within the 
normal range—is trending slowly 
downward year by year. People 
without plaques varied slightly, but 
overall their cognition held steady. 
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UNLOCKING THE SECHETS OF 
PET Alzheimer's 
IMAGING disease 
Some brain regions may show amyloid plaques earlier than others. Right: an average of PIB PET scans of volun- 
teers who were cognitively normal; scans created by subtracting background activity, left: correlating average MR 
image to show anatomy. When processed in this way, PET image shows in stark contrast specific areas of brain 
(outlined in red) that have subtle, but abnormal, amyloid binding of PIB. Identification of such brain regions may 
help to increase sensitivity in detecting amyloid plaques in the earliest stage. 
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The hippocampus is also 
closely linked to other parts of the 
brain through neural networks. 
Yvette Sheline, MD, professor of 
psychiatry, also working with 
Mintun, decided to see whether the 
interaction of the hippocampus 
with these areas (its "functional 
connectivity") is impaired in people 
with symptoms. Using a functional 
MRI method developed by Marcus 
Raichle, MD, professor of radiology 
and of neurology, and chief of the 
Institute's Neuroimaging Lab, they 
have been studying the "resting 
state connectivity" of the brain in 
patients with AD and in people with 
no cognitive impairment. Not sur- 
prisingly, the people with AD showed 
vastly different connectivity from 
those who did not have the disease. 
Using PIB and PET, they have 
taken that latter group of non- 
impaired people and separated 
them into those with plaques and 
those without. Now they are testing 
each of these groups using func- 
tional MRI to see whether there are 
connectivity differences. "And sure 
enough," says Mintun, "they had a 
subtle but very clear decrease in 
the connectivity of their hippocam- 
pus to other areas of their brain." 
All of these signals—decreasing 
cognition, a shrinking hippocampus 
and deteriorating functional con- 
nectivity—may eventually help 
researchers to establish whether 
the disease has begun and how far 
it has progressed. They will also 
help physicians decide who would 
most benefit from medication, thus 
sparing those who do not yet need 
it from the possible adverse effects 
of powerful drugs. 
* 
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Brain Inflammation 
Researchers hypothesize that 
one of the first things to happen in 
the AD process is the deposition of 
amyloid plaques in the brain. Then, 
years later, neurons begin to die. 
What causes them to die—and why 
such a long delay? A possible 
culprit is brain inflammation, and 
controlling it may be a critical com- 
ponent of helping people with AD. 
In a new project, Mintun and 
his group are partnering with 
Robert Mach, PhD, head of the 
Institute's Radiological Chemistry 
Lab, to develop better ways of 
imaging brain inflammation. Mach 
is trying to produce a new tracer 
that would bind to the inflamed 
cells, which would then show up 
on PET imaging. Though he is 
building on the foundation of a 
tracer developed several years ago, 
"We would like to develop a 
technique sensitive enough to see 
the types of inflammation that 
occur in Alzheimer's disease and 
then monitor them," says Mintun. 
"Does it correlate with the severity 
of the symptoms or with the 
number of amyloid plaques in the 
patient's brain? Is the inflammation 
different from one person to 
another? Does it track with how 
quickly the cognitive abilities are 
declining? These are all questions 
that are difficult to answer without 
an imaging tool." 
Looking to the Future 
As researchers move further 
into this new realm of experimenta- 
tion, it is clear that PET provides 
information that other methods 
cannot. Using molecular imaging, it 
can use trace amounts of mole- 
cules, noninvasively, to supply 
Researchers hypothesize that one of the first 
[things to happen in the AD process is the 
deposition of amyloid plaques in the brain... 
Mach has a difficult task ahead. 
The existing tracer binds only 
weakly to inflamed cells, so the 
resulting PET signal is not strong 
enough. Ideally, Mach hopes to 
develop one that is 10 times 
stronger, but still binds firmly 
to its targets. First, he will test 
proposed compounds in mice, 
and then in humans. 
unique feedback on biochemical 
and cellular processes in the 
human brain. And Mallinckrodt 
Institute is perfectly positioned to 
do this PET imaging, with its 
history as the place where PET 
was developed and its record of 
"firsts" in the field, says Mintun, 
who heads the Center for Clinical 
Imaging Research. 
While it is impossible to 
predict when clinical break- 
throughs may occur, Mintun and 
his colleagues remain optimistic 
that major advances will take place 
within this generation. So many 
researchers are tackling these 
problems, from so many directions, 
that there is a far better under- 
standing now of the mechanism of 
this terrible disease. And clinical 
treatments cannot come soon 
enough, he says, given the suffering 
of patients with AD and their families. 
Mintun illustrates the severity 
of AD with an anecdote from a pre- 
sentation he was giving with John 
Morris: "Doctor Morris asked a 
room full of people aged fifty and 
older, 'How many people here have 
survived cancer?' Hands went up. 
When he asked about heart attacks, 
again a lot of hands went up," 
says Mintun. "But when he asked 
how many had survived Alzheimer's 
disease, no hands were raised. AD 
is a relentless disease, one-hundred 
percent fatal. I am cautiously 
optimistic, but we are not there 
yet—and a lot of people 
are suffering." Pm 
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ancer treatment has come a long way but, as 
most would agree, not far enough. Cytotoxic 
chemotherapy, which works by damaging divided 
cancer cells and preventing their reproduction, 
has been around for nearly 60 years. 
of cancer treatment. While PET is 
effective at staging cancers and 
More recently, targeted therapies 
that preferentially bind certain 
cancer cells have emerged, but 
they're typically administered to 
itients along with cytotoxic drugs. 
is means a large percentage 
of patients with cancer are still 
exposed to highly toxic levels of 
chemotherapy during treatment 
and often experience debilitating 
adverse effects as a result. 
Positron emission tomography 
(PET)—an imaging technique 
developed at Mallinckrodt 
Institute in the early 1970s to 
measure bodily changes at the 
molecular level—is one of the 
methods used by oncologists to 
eliminate some of the guesswork 
detecting recurrence, current 
uses provide limited information 
as to whether a tumor will 
respond to certain therapies. But 
now, a new type of PET imaging 
may provide a more detailed 
assessment of tumors, thereby 
helping physicians to plan more 
effective treatment strategies. 
Researchers at Mallinckrodt Insti- 
tute recently began the first 
human studies investigating how 
imaging a certain cell receptor 
can allow better understanding 
about the size of a tumor and the 
likelihood that it will respond to 
certain treatments. 
! 
IMAGING THE BEHAVIOR 
OF CANCER CELLS 
Thus far, the use of PET scan- 
ning in oncology has largely focused 
on a metabolic tracer known as 
FDG, or flurodeoxyglucose. When 
a patient is injected with this 
radioactively labeled glucose, the 
PET scanner can detect differences 
in glucose use between tumors and 
healthy surrounding tissue. This 
measurement has proven useful in 
diagnosing and staging tumors but 
doesn't provide detailed information 
for guiding treatment. 
A new approach to using PET 
in cancer imaging involves using 
radiotracers that measure tumor 
proliferation at the cellular level. 
chemotherapy and to high- 
dose radiotherapy, the risk 
of using these treatments 
is worth the high likeli- 
hood of benefit. But 
tumors whose cells prolif- 
erate more slowly don't 
respond any better to 
aggressive radiation and 
chemotherapy, and in 
these cases the riskbenefit 
ratio is too high to make 
certain treatments worthwhile. 
These patients would then be 
treated with cell cycle nonspecific 
agents and conventional radiother- 
apy, thus being spared the toxicities 
of expensive treatments that are 
unlikely to be effective. 
In search of a method to image 
cell proliferation, cur- 
rently most researchers 
are using radiolabeled 
thymidine analogs 
with PET. Tumors 
undergoing rapid 
growth and division 
accumulate radiola- 
beled thymidine 
In the Tissue Culture Room, Justin Rothfuss, senior 
research technician, is using the inverted microscope; 
Fanjie Chang is at the bio-safety cabinet. 
"Thymidine is a good marker of 
DNA synthesis, but this method 
doesn't tell the whole story," says 
Robert Mach, PhD, chief of 
Mallinckrodt Institute's Radiological 
Chemistry Laboratory. "Imaging 
with radiolabeled thymidine 
analogs underestimates the true 
number of proliferating cells in a 
tumor—an important distinction 
in determining which treatment is 
best for the patient." 
"Looking at sigma-2 receptors to 
image proliferation is an entirely new 
approach, something different from 
what everyone else is doing..." 
Jinbin Xu, senior scientist, and (right) Robert Mach, 
PhD, are in the Quality Assurance Lab for PET radio- 
pharmaceuticals. 
Having a measurement of cell 
proliferation in patients with cancer 
is useful for a number of reasons, 
but particularly because it helps to 
determine what type of treatment 
is most appropriate for an individual 
patient. For instance, because fast 
growing tumors typically respond 
well to cell cycle specific 
analogs, which can be detected by 
PET imaging. When these agents 
are injected into a patient, the PET 
scanner measures the number of 
cells that are in a state called "S- 
phase" (the synthesis phase of the 
cell's life cycle). But only a small 
percentage of cells in a tumor will 
be in S-phase at any given time. 
After S-phase, cells continue to 
go through other phases of growth 
and division, including a resting 
period known as the Q-phase 
(quiescent). 
A NEW APPROACH 
TO IMAGING TUMORS 
Researchers are using a new 
method to image cell proliferation 
in tumors, using sigma-2 receptors 
to directly visualize a tumor's 
behavior. Sigma receptors, origi- 
nally thought to be a subtype of 
opiate receptors, are now recog- 
nized as a class of receptors 
expressed in normal tissues, 
including liver, kidneys, endocrine 
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Zhude Tu, PhD, research assistant professor of radiology, 
with the fluoride chemistry system used in the production 
of radiotracers. 
glands, and, to a lesser extent, the 
central nervous system. "Looking 
at sigma-2 receptors to image 
proliferation is an entirely new 
approach, something different 
from what everyone else is doing," 
says Mach, professor of radiology, 
of cell biology and physiology, and 
of biochemistry and molecular 
biophysics. 
As they relate to cancer treat- 
ment, sigma-2 receptors may be 
most impressive for their ability 
to reflect the entire life cycle of 
cancer cells. This is because the 
number of sigma-2 receptors in 
proliferating tumor cells is 10 
times higher than the number of 
receptors in quiescent (resting) 
tumor cells. This difference in den- 
sity means that imaging the sigma-2 
receptor status of tumor cells can 
provide an accurate measure of the 
tumor's overall proliferative status, 
known as the P (proliferating):Q 
(quiescent) ratio. Unlike the 
method that uses thymidine 
analogs, sigma-2 receptor imaging 
clearly differentiates between pro- 
liferating tumor cells and quiescent 
tumor cells. Furthermore, because 
the density of the 
sigma-2 receptor in 
quiescent tumor cells 
is higher than that 
reported in normal 
cells, this imaging 
strategy can also dif- 
ferentiate slow grow- 





of a method for pro- 
ducing accurate P:Q 
ratios are rewarding 
for oncologists and 
cancer patients alike. 
Many of today's cancer treatments 
are risky because of their high toxi- 
cities and price tags and, for that 
reason, physicians would prefer to 
know ahead of time how effective a 
particular treatment is likely to be. 
Sigma-2 receptor imaging may bring 
them closer to that goal. 
As solid tumors grow, even a 
few millimeters, they outgrow their 
blood supply. Areas of the tumor 
are deprived of nutrients and exit 
the cell cycle, a process that turns 
them into quiescent, or nongrow- 
ing, tumors. Quiescent tumors cells 
(the "Q" in the P:Q ratio) are more 
resistant to treatment 
than are proliferating 
tumor cells. That 
doesn't mean they're 
not dangerous, but 
rather that they are 
unlikely to respond to 
therapies that target 
rapidly growing cells. 
At top, sigma-2 receptors as 
viable strategy for determining 
proliferative status of solid 
tumors.  At bottom: MicroPET 
images (left column); Coregis- 
tered images (middle column); 
MicroCT images (right column). 
GO 
UNCOVERING LIGAND 
FOR HUMAN TRIALS 
Research on the sigma-2 recep- 
tor's role in reflecting cell prolifera- 
tion goes back to 1995, when Mach 
and Ken Wheeler, a cancer cell 
biologist from Wake Forest Univer- 
sity, began studying the expression 
of the receptor in tumor cell cul- 
tures in mice. Known as "66 cells," 
the cells came from a breast tumor 
line that grows in nutrient-deprived 
conditions. These cells would grow 
for four days, exit the cell growth 
cycle, and go into a resting phase. 
By observing this process, 
researchers were able to detect 
changes in tumor biology between 
P and Q cells. They found that the 
presence of sigma-2 receptors was 
10-fold higher in proliferating 
tumor cells than in quiescent tumor 
cells, and the presence of sigma-2 
in quiescent tumor cells was higher 
than in normal cells. Their research 
was published in Cancer Research 
and the British Journal of Cancer. 
Over the past seven years, the 
Mach research group turned this 
discovery into an imaging strategy 
ready to be used in human study 
volunteers. Since the concept was 
entirely new, everything had to be 
created from scratch—no small 
feat in the world of molecular 
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imaging. First they needed to find a 
way to image the receptors with 
PET scanning, which meant they 
had to develop a ligand to bind to 
the sigma-2 receptor. In most 
research of this type, scientists can 
choose from a few known ligands, 
cell proliferation with 
PET. In addition to pro- 
viding more information 
about the tumor itself, the 
scientists found the new 
technique yielded supe- 
rior image quality as com- 
"This may be useful for delivering treat- 
ments directly to the tumors, potentially 
triggering the cancer to kill itself..." 
but no such ligand was known for 
the sigma-2 receptor. After a five- 
year effort, the research team 
developed a sigma-2 selective mol- 
ecule that could be labeled with a 
radionuclide and tested in animal 
models of cancer; in the following 
years, they studied its use in imag- 
ing as well as its toxicity and 
dosimetry (the right amount of the 
agent to give and get a good picture 
without causing adverse effects). 
The animal studies concluded 
that radioligands with a high affin- 
ity and a high selectivity for sigma- 
2 receptors have the potential to 
noninvasively image solid tumor 
pared with other methods. The 
technique has been licensed by Iso- 
trace Technologies, Inc. and subli- 
censed to Bayer Schering Pharma 
AG, which will sponsor the first 
human clinical trials. 
In a study led by Farrokh 
Dehdasthi, MD, professor of radiol- 
ogy in Mallinckrodt Institute's Divi- 
sion of Nuclear Medicine, 
researchers are now trying to 
reproduce in humans the success 
found in the animal studies. The 
initial trials will focus on breast 
cancer since it's the type of cell 
originally validated in animal mod- 











Greg Gaehle, cyclotron manager, and (right) Robert 
Dennett, cyclotron supervisor, with the 10-ton, 
self-shielded Siemens RDS Eclipse cyclotron, which 
was installed in February 2002. Also shown are the 
target support unit and power supplies. 
Long-range plans include studying 
this type of imaging for the delivery 
of toxic agents. "Sigma-two recep- 
tors on the membrane, mitochon- 
dria, and endoplasmic reticulum 
are linked to the cell death path- 
way," explains Mach. "This may be 
useful for delivering treatments 
directly to the tumors, potentially 
triggering the cancer to kill itself." 
As scientists like Mach expand 
our ever-growing understanding of 
cancer, we look forward to safer 
and more effective treatments. 
Though it's likely to be some time 
before sigma-2 imaging makes it to 
the marketplace, the dedication 
that brought us here is what per- 
petuates cancer patients' hope for 
the future. Una 
Cell culture study showing high density of sigma-2 receptors in tumor cells 
(green). Tracker experiments show that sigma-2 receptors are not in the nucleus 
(DAPI/blue) but are in high localizations in the mitochondria and endoplasmic 
reticulum (both shown in red). The merger of images red and green (resulting in 
yellow for colocalization) suggest that sigma-2 receptors ligands may be useful in 
delivering anticancer agents to key intracellular organelles that regulate cell death. 
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IMAGING IS KEY TO ACCURATE DIAGNOSIS 
by Mary Jo Blackwood, RN, MPH 
Nothing is worse for a parent than to 
have a child in pain and not know what is 
causing the pain or what to do about it. 
Our greatest fears are about cancer, a massive infection, or a progressive 
chronic disease. Having a doctor rule out those conditions is only one 
step in determining what is causing your child's illness. 
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory 
disease that mostly affects children and young adults, is slightly more 
common in girls than in boys (a ratio of 5:1), and typically develops in 
children between the ages of four and 14 (with 10 being most common). 
While CRMO is noninfectious and noncancerous, the disease is often 
misdiagnosed because of its rarity—and that misdiagnosis can lead to 
multiple bone biopsies and long-term antibiotic therapy. 
WHAT IS CRMO? 
Geetika 
Khanna, MBBS, 













was a six-month-old 
c 
a bone lesion and then biopsy it. 
But there is no infection, only 
inflammation that occurs in the 
bone and typically in the long bones 
close to the growth plates, which 
can affect a child's growth if the 
inflammation is not brought under 
control. We're not sure why patients 
develop this condition, but it seems 
such as psoriasis and inflammatory 
bowel disease. Patients typically 
have debilitating, multifocal bone 
pain caused by the inflammation. 
Since the medical community 
became aware of the disease more 
than three decades ago, several 
hundred cases of CRMO have been 
reported. Because there is no 
'TYPICALLY AROUND THE AGE OF TEN, THESE 
CHILDREN PRESENT WITH BONE PAIN THAT SEEMS 
TO MOVE AROUND AND SOMETIMES WITH A 
LOW-GRADE FEVER..." 
IFOCAL     OSTEOMYELITIS 
infant. "Typically around the age 
of ten, these children present with 
bone pain that seems to move 
around and sometimes with a 
low-grade fever," she says. "With 
conventional X ray, we may detect 
to have some genetic component." 
CRMO is characterized by 
nonbacterial osteomyelitis, or 
bone inflammation with a remitting, 
relapsing course, and an association 
with other inflammatory disorders 
specific diagnostic test for CRMO, 
it remains a diagnosis of exclusion, 
making it likely that the number of 
cases is much higher than reported. 
Why people develop CRMO 
remains somewhat elusive. "The 
association of CRMO with derma- 
tologic disorders such as psoriasis 
and inflammatory bowel disease, 
along with its response to steroids, 
indicates a possible autoimmune 
etiology. More recently, a genetic 
etiology has been suggested, based 
on observation of the disease in 
siblings and monozygotic twins," 
says Khanna. "Another fact point- 
ing to a genetic cause is Majeed 
syndrome, an autosomal recessive 
disorder of CRMO with congenital 
dyserythropoietic anemia, which is 
associated with mutations in the 
LPIN-two gene." 
Geetika Khanna, MD, in the entrance to the Jack 
Buck Imaging Center at St. Louis Children's Hospital 
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A  CASE  STUDY 
An eight-year-old girl pre- 
sented with acute onset pain 
in her left hip. One month 
alter presentation, plain radi- 
ographs showed a lytic lesion 
at the greater trochanter (part 
of the thigh bone); biopsy 
revealed nonspecific inflam- 
mation. Two years later, the 
patient developed severe 
pain in the chest wall. A 
chest X ray showed an 
expanded sclerotic right- 
third rib with permeative 
lytic areas. Bone biopsy 
showed nonspecific inflam- 
mation. Magnetic resonance 
imaging of the chest con- 
firmed the inflammatory 
lesion of the rib and revealed 
additional vertebral body 
lesions. A diagnosis of 
CRMO was suggested, and 
the patient was started on 
anti-inflammatory therapy. 
She has had no major dis- 
ease exacerbations for two 
years since starting 
methotrexate. She continues 
to have intermittent short- 
lived episodes ot mild bone 
pain, but they do not interfere 
with her activities. 
MAKING THE DIAGNOSIS 
The disease has characteristic 
findings— including lesions in the 
metaphyses of long bones (such as 
in the leg) and the medial clavicle 
(or collarbone)—and is most often 
diagnosed by a radiologist due to 
its typical imaging findings. The 
metaphyses are the primary site of 
OTHER COMMON SITES 
FOR THE DISEASE 
INCLUDE THE VERTE- 
BRAL BODIES, PELVIS, 
RIBS, AND MANDIBLE. 
CRMO IS OFTEN BILAT- 
ERAL AND MULTIFOCAL 
AT PRESENTATION. 
bone growth in children. Because 
of their rich blood supply, the 
metaphyses of long bones are prone 
to hematogenous spread of infection 
in children. Hence, a bone biopsy is 
often required to exclude the possi- 
bility of infectious osteomyelitis or 
a tumor such as histiocytosis. 
Other common sites for the 
disease include the vertebral 
bodies, pelvis, ribs, and mandible. 
CRMO is often bilateral and multi- 
focal at presentation. However, 
because many of the lesions are 
asymptomatic at any given time, 
the patient may undergo conven- 
Classical findings of CRMO as seen in the case study: 
sclerosis and expansion of the medial clavicle, unilat- 
eral sacroilitis, vertebra piano and involvement of 
contiguous vertebral bodies with sparing of the inter- 
vening disc space. 
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tional radiographs for the painful 
area, which, without information 
about other bone involvement, may 
lead to an erroneous diagnosis. As 
the imaging appearance of CRMO 
can mimic other entities like infec- 
tion and tumors, awareness of 
other asymptomatic sites of disease 
can aid the diagnosis of CRMO. 
While at the University of Iowa, 
one of Khanna's patients was a girl 
who had undergone multiple surg- 
eries on her jaw and was on long- 
term antifungal treatment. When 
Khanna performed more extensive 
imaging, she found lesions in the 
girl's clavicle, a classic marker for 
CRMO, and unique among bone 
conditions in its involvement of 
the clavicle. 
According to Khanna, magnetic 
resonance imaging (MRI) can 
demonstrate associated periostitis, 
soft tissue inflammation, and 
synovitis—findings initially 
believed to be more typical for 
infectious osteomyelitis rather than 
CRMO. MRI is more sensitive than 
conventional imaging in detecting 
transphyseal spread of disease, 
which can result in growth defor- 
mities and, thus, has prognostic 
significance. 
TREATMENT FOR CRMO 
Nonsteroidal anti-inflammatory 
drugs (NSAIDs), such as aspirin 
and ibuprofen, are the mainstays of 
therapy, and most patients do quite 
well on these. For patients who do 
not respond to NSAIDs, treatment 
may include steroids, methotrexate, 
were referred to the University 
of Iowa's Department of Pediatric 
Rheumatology: 10 boys and 15 girls 
with an average onset of symptoms 
at 8.3 years. Khanna and Ferguson 
found these sites of disease at 
initial presentation to be the 
most common: lower extremities 
MRI IS MORE SENSITIVE THAN CONVENTIONAL IMAGING 
IN DETECTING TRANSPHYSEAL SPREAD OF DISEASE, 
WHICH CAN RESULT IN GROWTH DEFORMITIES AND, 
THUS, HAS PROGNOSTIC SIGNIFICANCE. 
and other immunosuppression 
drugs, particularly when CRMO is 
associated with a rash, arthritis, 
and a high probability of growth 
deformities. 
FURTHERING EFFECTIVE 
DIAGNOSIS OF CRMO 
While at the University of Iowa, 
Khanna worked closely with her 
rheumatology colleague Polly Fer- 
guson, MD, observing patients and 
reviewing imaging studies sent 
from all parts of the country and 
even some from outside the United 
States. They compiled case after 
case of diagnosed CRMO, with all 
of its variations in individual chil- 
dren. Twenty-five cases of CRMO 
(39.7 percent), spine (25.9 percent), 
and pelvis (20.7 percent). During 
the three-year average follow-up 
care, a total of 121 bone lesions 
were seen in this patient population 
of 25. Metaphyseal lesions were the 
most common, accounting for 49 
percent of all bone lesions. 
Their initial research findings 
were presented in 2008; subsequent 
findings will be published in the 
July 2009 issue of RadioGraphics. 
Radiological evidence is still being 
collected, both at the University of 
Iowa and at Mallinckrodt Institute, 
to amass information needed for 
future clinical trials on the identifi- 
cation and treatment of CRMO. 
MY 
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FUTURE DIRECTIONS FOR CRMO 
In September 2008, a National 
Institutes of Health conference/ 
CRMO workshop was held in 
Bethesda, Maryland, bringing 
together international clinical and 
and scoring of CRMO bone lesions 
to assess response to treatment. A 
Washington University colleague, 
Deborah Novack, MD, assistant 
professor of pathology and immunol- 
ogy, spoke on the immunological 
...THE GOAL OF CREATING A CONSENSUS FOR THE 
DEVELOPMENT OF STUDY INCLUSION CRITERIA, 
OUTCOME MEASURES TO IDENTIFY RESPONSE TO 
TREATMENT, AND BIOMARKERS OF DISEASE ACTIATTY. 
research experts to define the crite- 
ria for diagnosis of this condition 
and to identify the clinical markers 
that can be used for future clinical 
trials. At the conference, Khanna's 
presentation focused on using mul- 
timodality imaging for diagnosis 
evaluation of CRMO bone lesions. 
Following the presentations on 
state-of-the-art technology in all 
aspects of this disease, conference 
attendees participated in concurrent 
workshops focusing on scoring of 
imaging findings, skin scoring, 
study entry criteria, rheumatology 
and rehabilitation endpoints, and 
biomarkers for inflammation, bone, 
and GI tract—with the goal of 
creating a consensus for the 
development of study inclusion 
criteria, outcome measures to 
identify response to treatment, 
and biomarkers of disease activity. 
The proceedings from this workshop 
will be used to develop a multicen- 
ter trial for follow-up care of 
children with CRMO. EM 
CLINICAL  PRESENTATION  OF  CRMO 
• History of pain, tenderness, swelling, and limited 
range of joint motion 
'Duration of symptoms: from a few days to 
several years 
»Inconclusive laboratory findings, such as a mildly 
elevated ESR (erythrocyte sedimentation rate or 
how fast red blood cells fall through a column of 
blood) and CRP (C-reactive protein found in 
blood in response to inflajja^""^anri ■•■mal 
WBC (white blood c- 
A 
A-ray inaicdiiori 01 
bones near physe 
>Bone scan or magnetic resonance imaging reveai 
bilateral, multifocal areas of bone inflammation, 
even if asymptomatic 
>Most common bones affected: the long bones, 
medial clavicle. Other common sites: vertebral 
bodies, ribs, and mandible 
> Possible other symptoms: skin lesions 
(eg, psoriasis) and inflammatory bowel conditions 
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Assessing  breast  cancer  treatment 
by Amy Thomas, MD, FAAP 
As the most common cancer in females, 
breast cancer ranks high as a potential threat to a woman's vitality. But as physicians and 
scientists understand more about the nature of breast cancer, new treatments are being 
discovered and women are living longer even when they have advanced disease. Recently, 
research conducted at Mallinckrodt Institute of Radiology has made a marked contribution 
to the race for a cure—a novel way of assessing the best treatment for breast cancer in 
patients who have exhausted most available therapies. This new approach to a common 
imaging technique allows doctors to predict a tumor's response after only a few days of 
treatment. The insight gained not only helps to guide patients with limited options to the 
next best treatment choice, but it also unlocks incredible potential for the investigation of 
new breast cancer treatments that, hopefully, will give women even more time for life. 
"IWOF CANC 
he Discovery targets 
Ja key question in treating breast 
cancer: Will the tumor respond to 
hormone manipulation? The presence 
of functioning hormone receptors on 
breast cancer tumor cells, including 
those that react with estrogen or 
progesterone, suggests the cancer will J 
respond to a number of hormone 
therapies and generally will be mum 
easier to treat as compared with tumors1 
that lack hormone receptors. Though 
it is simple to detect the presence of 
hormone receptors on a newly diag- 
nosed cancer, doctors do not always 
know whether or not the receptors are 
functioning and if the tumors will 
respond to hormone therapy. This is 
especially problematic in patients with 
metastatic disease because some 
tumors lose their receptors over time, 
while others continue to have hormone 
receptors that are longer functioning. 
Farrokh Dehdasthi, MD, professor of 
radiology in Mallmckrodt Institute's 
Division of Nuclear Medicine, is investi- 
gating the ability of an imaging test to 
determine the functional status of 
hormone receptors—a simple set of 
pictures to predict how an individual's 
tumor will respond to treatment. 
Predicting patients' response 
to hormone therapy 
Dehdashti currently is studying 
a breast cancer phenomenon called 
"flare"—breast cancer's paradoxical 
response to treatment that will 
eventually be effective. One in 20 
women who receive hormone 
therapy for breast cancer will 
experience an initial phase of 
tumor growth, and this is the flare 
response. It typically indicates that 
after the initial growth phase, the 
tumor will respond well to hormone 
often impractical for patients with 
metastatic disease whose tumors 
are hard to reach. This leaves the 
remaining patients and their doctors 
with a difficult decision: try addi- 
tional hormone agents or move on 
to other lines of treatment. 
Though clinical flare is helpful 
in predicting response to treatment, 
only a small portion of women with 
breast cancer will experience phys- 
ical signs of flare, such as swelling 
or pain at the site of the tumor or 
tumor metastasis. A larger portion 
One  in 20 women who receive  hormone 
therapy for breast cancer will experience 
an initial phase of tumor growth,  and 
this  is  the flare response. 
therapy and subside with further 
treatment. More simply put: If a 
tumor reacts to the administration 
of hormones either by growing 
or shrinking, it must have function- 
ing receptors. 
Once doctors know that the 
hormone receptors are functioning, 
they can offer the patient a number 
of hormonally derived cancer 
treatments that are less toxic and 
less expensive than traditional 
chemotherapy. And those women 
with unresponsive tumors can 
proceed with therapies that have a 
better chance of helping their 
particular tumor. Biopsy can 
differentiate whether a tumor has 
receptors, but many tumors with 
receptors present still do not 
respond because the receptors are 
not functioning. And biopsy is 
of women will have a response 
termed "subclinical flare" in which 
the tumor does have a short period 
of growth related to treatment, but 
the patient has no physical indica- 
tion this is happening. Since it is 
known that women with any flare 
reaction tend to respond well to 
hormone therapy, doctors have 
looked for a way to detect which 
women have subclinical flare 
and should also be treated with 
continued hormonal therapy. 
In her past and current research, 
Dehdashti is finding new ways to 
determine the functional status of 
estrogen receptors, including the 
ability to use positron emission 
tomography (PET) to detect the 
presence of subclinical flare. The 
idea of imaging flare originated 
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from the known effects of tamox- 
ifen, an agent often used to treat 
hormone-responsive breast cancer. 
Tamoxifen is a hormone-blocking 
agent that has pro-estrogen effects 
for approximately the first seven 
days it is given to a patient. The 
initial pro-estrogen phase is then 
followed by an anti-estrogen effect 
that is often used to treat women 
with hormone-responsive breast 
cancer. "If we can assess the 
effect of tamoxifen on the estrogen 
receptor, we can determine the 
receptor's functional status," 
says Dehdasthi. 
Detecting subclinical flare 
Dehdasthi is able to visualize 
a tumor's response to a hormone 
challenge by using PET, which 
detects a growing cancer's hearty 
appetite for glucose. A patient is 
injected with glucose combined 
with a radioactive tracer (fluorine- 
18 fluorodeoxyglucose, or FDG), 
and the PET scanner is able to 
detect and localize the tagged 
glucose within the body. PET imag- 
ing takes advantage of the fact that 
rapidly growing cells, like cancer 
cells, use more glucose than normal 
cells, and typically a cancer will 
have an increase in glucose 
utilization during a growth spurt. 
"If we can assess 
the effect of 
tamoxifen on the 
estrogen receptor, 
we can determine 
the receptor's 
functional status" 
Dehdashti and Siegel are in the PET-CT scanning area in MIR's Center for Clinical Imaging Research, the nation's 
only research-dedicated, comprehensive imaging facility in the center of a major hospital. 
By performing a baseline PET scan 
followed by a repeat PET scan 
about one week after a patient 
begins taking tamoxifen, doctors 
can predict response by comparing 
the difference in tumor activity on 
each scan. If the demand for glu- 
cose increases just after tamoxifen 
is introduced, then it is clear that 
the estrogen receptors are respond- 
ing and functional. In other words, 
the patient is experiencing a flare 
response, known by doctors as 
"metabolic flare." In more recent 
studies, Dehdashti has shown that 
the flare can be detected after just 
one day of tumor stimulation with 
an estrogen drug. 
Once the detection of flare 
determines a patient's tumor has 
functioning hormone receptors, 
that patient can then begin or 
resume hormone therapy knowing 
there is a high likelihood the tumor 
will respond to treatment. If the 
receptors are shown to be unre- 
sponsive by imaging, the doctor 
knows the tumor is unlikely to 
respond to a course of hormone 
therapy and can move on to more 
aggressive chemotherapies for 
treatment. The ability to treat a 
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BASELINE 
^ -A^ // 
24 HOURS AFTER ESTRADIOL 
SUV = 6.4 
SUV = 8.3 
In bottom right image, metabolic flare reaction is 
shown as a 12% or greater increase in standardized 
uptake value (SUV), indicating a response to 
endocrine therapy. 
cancer with hormone therapy is 
advantageous for many reasons: 
• Hormone therapy is generally less 
toxic than chemotherapy. 
• The adverse effects are generally 
better tolerated than those 
related to chemotherapy. 
• The cost of using hormones to 
treat cancer is significantly less 
than with other treatments. 
Impact on quality of life 
Barry Siegel, MD, professor of 
radiology and of medicine, and 
chief of Mallinckrodt Institute's 
Division of Nuclear Medicine, has 
"..♦We must show not only that this 
technique can properly predict response, 
hut that it also improves the quality 
of a patient*s life" N 
collaborated with Dehdasthi in 
looking at PET's ability to detect 
flare. "The results are encouraging," 
says Siegel. "Now we must look at 
survival data and compare out- 
comes, adverse effects, and cost." 
The next step for researchers 
is to compare whether the use 
of PET to predict flare makes a 
significant difference in the lives 
of those with breast cancer. "We 
know it's good, but is it good 
enough? We must show not only 
that this technique can properly 
predict response, but that it also 
improves the quality of a patient's 
life," says Siegel. 
Matthew Ellis, MB, BChir, PhD, 
professor of medicine, is enthusias- 
tic about Dehdashti's work. He 
is head of the Medical Oncology 
section at Washington University 
School of Medicine (WUSM) and 
director of the Breast Cancer 
Program at the Alvin J. Siteman 
Cancer Center at WUSM and 
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Barnes-Jewish Hospital. Ellis relies 
on knowing the functional status 
of estrogen receptors to provide 
the right treatment for his patients. 
"For patients with estrogen recep- 
tor [ERJ-positive breast cancer, the 
manipulation of estrogen levels is 
critical to treatment. But it doesn't 
work in everyone, even in the pres- 
ence of ER-positive tumors. The 
goal is to predict who will do well." 
Improving clinical research 
In addition to its potential for 
clinical use, the ability of PET to 
predict the functional status of 
estrogen receptors in breast 
tumors is also a great boost to 
research. Therapeutic agents 
designed for use on hormonally 
responsive tumors can be tested on 
those likely to respond. "This helps 
us to study the effectiveness of 
\       "This helps us to study the effectiveness 
|       of new therapies without fighting the 
|       battle against tumors that would he 
unresponsive  anyway" 
Ellis recently collaborated with 
Dehdashti and Siegel in studying an 
estrogen regimen for patients with 
metastatic breast cancer who have 
become resistant to certain treat- 
ments. The investigators suspect 
that daily estrogen therapy could 
wipe the resistance slate clean in 
some patients who have exhausted 
other options, and that PET could 
be a useful 
predictor of 
likely success 






Ellis is a member 
of the Breast Cancer 




new therapies without fighting the 
battle against tumors that would be 
unresponsive anyway," says Ellis. 
By eliminating the subset of tumors 
that wouldn't respond to any hor- 
mone manipulation, researchers 
can get a better idea of a new agent's 
efficacy in the target group of 
patients with functioning hormone 
receptors on their tumors. 
And it is these newer and 
more effective agents thought to 
be, in part, responsible for the 
improvement seen in breast cancer 
patients' survival. Even women 
with advanced disease are living 
longer with the treatments avail- 
able now. As scientists investigate 
treatments for those who have 
exhausted their options, new 
research is bringing hope to those 
who had none. And the research 
at Mallinckrodt Institute is already 
changing the clinical practice 
across the United States. ED3 
Risk factors for 
breast cancer 
gender—100 times more common 
among women than men 
aging—risk doubles in women 
aged 55 years or older 
family history—20% to 30% of 
women with the disease have a 
family member with the disease 
race and ethnicity—Caucasians 
are slightly more likely to develop 
the disease than are other races 
or ethnicities 
dense breast tissue—more 
glandular tissue and less fatty tissue 
increase risk 
lifestyle-related factors— 
including use of alcohol, being 
overweight or obese, lack of 
physical activity 
Information excerpted from the 
American Cancer Society Web site 
at www.cancer.org. 
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NEW FACULTY 
Larry Bretthorst, PhD, 
research associate professor 
of radiology, Division of 
Radiological Sciences. 
Monica Shokeen PhD, 
instructor in radiology, Divi- 
sion of Radiological Sciences. 
Thaddeus Wadas, PhD, 
instructor in radiology, Divi- 
sion of Radiological Sciences. 
PROMOTIONS 
Barry Edwards, PhD, 
research instructor in 
radiology, was promoted 
to assistant professor of 
radiology, Division of 
Radiological Sciences. 
David Gierada, MD, associ- 
ate professor of radiology, 
was promoted to professor 
of radiology, Division of 
Diagnostic Radiology. 
Michael Penney, MD, 
instructor in radiology, was 
promoted to assistant pro- 
fessor of radiology, Division 
of Diagnostic Radiology. 
Suresh Vedantham, MD, 
associate professor of radiol- 
ogy, was promoted to profes- 
sor of radiology, Division of 
Diagnostic Radiology. 
Daniel Wessell, MD, PhD, 
instructor in radiology, was 
promoted to assistant pro- 
fessor of radiology, Division 
of Diagnostic Radiology. 
JOINT 
APPOINTMENTS 
Jin-Moo Lee, MD, PhD, 
associate professor of neurol- 
ogy, was appointed associate 
professor of radiology, Divi- 
sion of Radiological Sciences. 
Suresh Vedantham, MD, 
professor of radiology, was 
appointed professor of 
surgery, Department of 
Surgery. 
Younan Xia, PhD, professor 
of biomedical engineering, 
was appointed professor of 
radiology, Division of Radio- 
logical Sciences. 
GRANTS  
Carolyn Anderson, PhD, 
professor of radiology, of 
molecular biology and phar- 
macology, of chemistry, and 
of biochemistry, as principal 
investigator, received a 
$292,410 four-year renewal 
grant from the National Insti- 
tutes of Health for research 
on "Labeling of octreotide 
with positron emitters." 
Thomas Conturo, MD, 
PhD, associate professor of 
radiology, of physics, and of 
biomedical engineering, as 
principal investigator, 
received a $456,000 grant 
from the U.S. Department of 
Defense to study "Breast 
cancer diagnosis and therapy 
monitoring." Collaborators 
for the three-year grant are 
Erbil Akbudak, PhD, 
research assistant professor 
of radiology, and Hsui-San 
Lin, MD, PhD, Washington 
University Department of 
Radiation Oncology. Con- 
turo, as subcontract 
principal investigator, and 
Rob Paul, PhD, University 
of Missouri, St. Louis, as 
overall principal investiga- 
tor, received a $3.1 million 
grant from the National Insti- 
tutes of Health for research 
on "Neuromarkers of age- 
related cognitive decline." 
Collaborators for the five-year 
grant are Akbudak, Eren 
Gultepe, and Amanda 
McMichael, MS. 
Steven Don, MD, associate 
professor of radiology, 
received the Society for 
Pediatric Radiology's 2009 
John Dorst-Felix Fleischner 
Seed Grant of $10,000 for 
research on "Mathematical 
modeling of pediatric 
pulmonary nodules." 
Fred Prior, PhD, research 
associate professor of radiol- 
ogy, as principal investiga- 
tor, received a one-year, 
$1.9 million grant from the 
National Institutes of Health 
to fund the project "High 
performance biomedical 
imaging computer resources." 
Yuan-Chuan Tai, PhD, 
associate professor of radiol- 
ogy, as principal investigator, 
received a $2.2 million grant 
from the National Cancer 
Institute, National Institutes of 
Health, for "A sub-millimeter 
resolution add-on for animal 
PET scanners." Stefan 
Siegel, Siemens Molecular 
Imaging, KnoxvUle, Tennessee, 
is coprincipal investigator 
for the five-year grant; 
Joseph O'Sullivan, PhD, 
Washington University 
Department of Electrical 




Bennett Greenspan, MD, 
instructor in radiology, was 
named editor of the Nuclear 
Medicine Science Syllabus, 
5th edition, published by the 
American Board of Science 
in Nuclear Medicine. 
Nassir Siddiqi, MD, assis- 
tant professor of radiology, 
was elected chairman of the 
Continuing Medical Educa- 
tion Committee of the King 
Edward Medical College 
Alumni Association. He was 
appointed to membership of 
the Society of Interventionsj 
Radiology's Standards of 
Practice Committee, the 
Publications Advisory Conv 
mittee, and the Oncology 
Task Force. He also was 
appointed to the Washingto 
University in St. Louis Insti- 
tutional Review Board. 
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HONORS/AWARDS    LECTURES 
I 
Samuel Achilefu, PhD, 
professor of radiology and of 
biochemistry and molecular 
biophysics, was named ses- 
sion chair of "New activation 
strategies in molecular imag- 
ing" at the 100th Annual 
Meeting of the American 
Association for Cancer 
Research, Denver, Colorado, 
April 18-22. 
Naganathan Mani, MD, 
instructor in radiology, 
received the eighth highest 
score among all physicians 
who participated in the 
Korean Society of Thoracic 
Radiology's 2008 weekly 
chest case quiz. 
Fred Prior, PhD, research 
associate professor of radiol- 
ogy, received his fifth year 
of funding as a Subject 
Matter Expert for the Cancer 
Bioinformatics Grid (caBIG) 
program. 
Samuel Achilefu, PhD, 
professor of radiology and of 
biochemistry and molecular 
biophysics, as Ground 
Rounds Speaker, presented 
"Optical imaging: a unique 
and complementary imaging 
modality" at Thomas Jeffer- 
son University, Philadelphia, 
Pennsylvania, February 24. 
He spoke on "Optical tech- 
niques of bioluminescence 
& fluorescence" at the Inter- 
national Symposium on 
Molecular Imaging and Ther- 
apy: Road Map to Modern 
Medicine, Kuwait University, 
Kuwait City, March 9-12. He 
presented "Flip-flopping 
contrast mechanisms in 
molecular optical imaging 
of tumor cells and tissues" 
as part of the Faculty of 
Graduate Studies Lecture 
Series, Loma Linda Univer- 
sity, California, April 14. 
Carolyn Anderson, PhD, 
professor of radiology, of 
molecular biology and phar- 
macology, of chemistry, and 
of biochemistry, spoke on 
"Copper-64-labeled biomole- 
cules for molecular imaging 
of cancer metastasis" at the 
Duke University Workshop: 
Clinical Directions for Mole- 
cular Imaging, Durham, 
North Carolina, March 12, 
and at Johns Hopkins Uni- 
versity, Baltimore Maryland, 
March 25. She presented 
"Nuclear and radiochemistry 
at Washington University in 
St. Louis" at the MARC VIII 
Conference, Kona, Hawaii, 
April 15-10. 
Delphine Chen, MD, assis- 
tant professor of radiology, 
spoke on "Imaging intracel- 
lular markers of apoptosis" 
at the Transatlantic Airway 
Conference, sponsored by 
Boehringer-Ingelheim, 
Lucerne, Switzerland, Janu- 
ary 22 and 23. She presented 
"FDG-PET imaging as a bio- 
marker for neutrophilic lung 
inflammation" as part of the 
Nuclear Medicine Research 
Seminar Series, Massachusetts 
General Hospital, Boston, 
April 3. 
Nirvikar Dahiya, MD, 
assistant professor of radiol- 
ogy, presented "Acquiring a 
3-dimensional ultrasound 
image: basic principles" and 
moderated "Nonobstetric 
applications of a 3-dimen- 
sional ultrasound: improving 
productivity and workflow" 
at the 2009 Annual Conven- 
tion of the American Institute 
of Ultrasound in Medicine, 
New York City, April 2-5. He 
spoke on "Ultrasound evalu- 
ation of liver transplant and 
ultrasound evaluation of 
thyroid lesions" at USCON 
XVIII, the Annual Conference 
of the Indian Federation of 
Ultrasound in Medicine and 
Biology, Goa, India, April 30- 
May3. 
Biello Lecture 
Chaitanya Divgi, MD, professor of 
radiology, University of Pennsylvania; 
chief, Nuclear Medicine and Clinical 
Molecular Imaging, Hospital of the 
University of Pennsylvania, Philadelphia, 
was guest speaker for the Twenty-third 
Annual Daniel R. Biello Memorial Lecture 
on March 11. He presented "Back to the 
future in nuclear medicine: developments 
and integration." 
Divgi (left) with Barry Siegel, MD, thief, Division of Nuclear Medicine. 
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LECTURES Section on Cerebrovascular Disease, San Diego, Califor- 
nia, February 17. He presented 
"Stenting versus Aggressive 
Medical Management for the 
Prevention of Ischemic Stroke 
(SAMMPRIS) Trial update" 
at the 34th International 
Stroke Conference,. San Diego, 
California, February 20. 
Louis Gilula, MD, 
professor of radiology, of 
orthopaedic surgery, and of 
plastic and reconstructive 
surgery, spoke on "A two- 
year follow-up for intergroup 
study of Cortoss™ for verte- 
broplasty" at the 2009 
Annual Symposium of the 
American Society of Spine 
Radiology, Lake Buena Vista, 
Florida, February 19-22. He 
presented "Imaging interpre- 
tation of hand and wrist, 
emphasis on trauma" at the 
41st International Diagnostic 
Course, Davos, Switzerland, 
March 29-April 30. 
Continued from page 29 
Colin Derdeyn, MD, pro- 
fessor of radiology and of 
neurology and neurological 
surgery, presented 
"Overview of cerebral hemo- 
dynamics" at the 9th Annual 
International Meeting on 
Cerebral Revascularization, 
St. Louis, Missouri, January 
8; at Radiology Grand 
Rounds, Department of Radi- 
ology, University of Virginia, 
Charlottesville, March 9; and 
at the Alleghany Regional 
Hospital Neuroscience 
Grand Rounds, Pittsburgh, 
Pennsylvania, March 25. He 
spoke on "Intracranial ather- 
osclerotic disease and the 
SAMMPRIS Trial" at the 
Cedars-Sinai Neurovascular 
Symposium, Los Angeles, 
California, January 10. 
Derdeyn spoke on "Natural 
history of intracranial ather- 
osclerotic disease" at the 
annual meeting of the Joint 
In January 2009, Louis Gilula, MD, professor of radiol- 
ogy, of orthopaedic surgery, and of plastic and recon- 
structive surgery, was invited, as a radiology expert, by 
the Singapore Ministry of Health to present a series of 
lectures to the departments of radiology at five medical 
facilities: Changi General Hospital, Singapore General 
Hospital, Alexandra Hospital, National University Hospi- 
tal, and Tan Tock Seng Hospital.   He gave the following 
presentations: "Board review tutorial to residents," 
"Entities of the wrist which are not commonly known," 
"Analysis of complex carpal trauma," "Vertebroplasty: 
basic principles and technical aspects," "Radiographic 
findings in hand and wrist surgery," "Approach and 
overview to trauma," "Cervical spine nerve blocks," 
"Nerve root blocks and central epidural blocks for neck 
and low back pain," "Cervical spine trauma," "Facet 
blocks and radiofrequency ablation of facet nerves," 
"Ligamentous instabilities of the wrist," and "Vertebro- 
plasty: current status and problem solving." 
Bennett Greenspan, MD, 
instructor in radiology, 
presented "Diagnosis and 
therapy of hyperthyroidism" 
at Grand Rounds at the Habif 
Health and Wellness Center, 
Washington University in St. 
Louis, January 14. 
Perry Grigsby, MD, profes- 
sor of radiation oncology, of 
radiology, and of gynecologic 
oncology, spoke on "The use 
of PET/CT for simulation, 
treatment planning, and 
IMRT guided therapy for cer- 
vical cancer" and "The use of 
PET/CT in cervical cancer 
to assess response during 
therapy, after completion of 
therapy, and for long-term 
follow-up" at the 2009 First 
Multidisciplinary PET/CT 
Oncology Symposium, 
San Juan, Puerto Rico, 
January 31. 
Jay Heiken, MD, professor 
of radiology, spoke on 
"Distinguishing benign from 
malignant liver tumors," "CT 
and MR in the detection and 
staging of pancreatic can- 
cer," "Evaluation of the liver 
after transarterial chemoem- 
bolization," and "Contrast 
safety in the cancer patient" 
at the first RSSA/ICIS Cancer 
Imaging Course, sponsored 
by the Radiological Society 
of South Africa and the Inter- 
national Cancer Imaging 
Society, Cape Town, South 
Africa, February 6-8. He pre- 
sented "Abdominal aortic 
aneurysm rupture," "CIN and 
contrast use in subjects with 
renal dysfunction," "MDCT 
of bowel obstruction," "CT 
colonography techniques," 
and "CT colonography clini- 
cal trial results" at Masters in 
Body Imaging, 2009 Annual 
Course of the Society of 
Computed Body Tomography 
and Magnetic Resonance, 
Miami Beach, Florida, 
March 1-6. As a visiting 
professor, he spoke on 
"Acute mesenteric ischemia: 
MDCT evaluation" and "Cys- 
tic pancreatic neoplasms: 
diagnosis and clinical man- 
agement" at Yale University, 
New Haven, Connecticut, 
April 2. 
Charles Hildebolt, DDS, 
PhD, professor of radiology 
and of anthropology, pre- 
sented "Virtual hobbits and 
health in Homo floresiensis" 
at Hobbits in the Haystack: 
Homo floresiensis and 
Human Evolution, the 
Seventh Human Evolution 
Workshop sponsored by the 
Turkana Basin Institute, at 
Stony Brook State University 
of New York, April 21. 
Rebecca Hulett-Bowling, 
MD, assistant professor of 
radiology, spoke on "Imaging 
of pediatric tuberculosis and 
other infections" at the 
Queen Elizabeth Hospital, 
Maseru, Kingdom of 
Lesotho, Africa, February 16. 
Seung Kwon Kim, MD, 
assistant professor of radiol 
ogy, presented "Fluoroscopi'' 
placement of self-expanding 
metallic stent for the treat- 
ment of obstructing left-side I 
colorectal cancer" at the 
European Congress of 
Radiology, Vienna, Austria, 
March 6-10. 
Robert McKinstry, MD, 
PhD, associate professor o 
radiology and of pediatrics, 
as Radiology Grand Round; 
speaker, presented "Imagin 
of brain injury in newborns 
and "Neuroradiology cases 
from the Mallinckrodt 
Institute of Radiology" at 
Brigham and Women's Hos 
pital, Boston, March 31, am 
at Massachusetts General 
Hospital, Boston, April 1. 
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Michelle Miller-Thomas, 
MD, instructor in radiology, 
spoke on "Temporal bone 
|   imaging" at the University 
of Texas Health Sciences 
Center, Houston, March 16. 
Nassir Siddiqi, MD, assis- 
tant professor of radiology, 
;   spoke on "Chemoemboliza- 
tion for liver tumors" at the 
Nurses Continuing Educa- 
tion Lecture, sponsored by 
Barnes-Jewish Hospital and 
the Center for Advanced 
Medicine, St. Louis, Missouri, 
March 6. He presented 
"Venous thromboembolism 
and IVC filters" at the King 
Edward Medical College 
Alumni Annual Meeting, 
St. Louis, Missouri, March 28. 
Barry Siegel, MD, professor 
of radiology and of medicine, 
presented "Sponsorship and 
economics of imaging trials 
and research billing compli- 
ance" and "Practicalities of 
running a clinical trial" at the 
Radiological Society of 
North America Clinical Tri- 
als Methodology Workshop, 
Phoenix, Arizona, January 
10-16. He spoke on "PET 
reimbursement and the 
National Oncologic PET Reg- 
istry" and "PET and PET/CT 
in oncology: monitoring and 
predicting response to 
therapy" at the 2009 First 
Multidisciplinary PET/CT 
Oncology Symposium, San 
Juan, Puerto Rico, January 
31. He spoke on "Update on 
reimbursement of PET and 
the NOPR" and "Cervical 
cancer" at Advances in 
Whole Body Fusion Imaging: 
PET/CT and SPECT/CT, 
Johns Hopkins University, 
Baltimore, Maryland, March 
13 and 14. Siegel presented 
the Fifth Annual Maxfield 
Lecture—"PET reimburse- 
ment and NOPR"—and "PET 
& PET/CT: predicting and 
monitoring response to 
therapy" at the 54th Annual 
Meeting of the Southwestern 
Chapter, Society of Nuclear 
Medicine, Houston, Texas, 
March 20-22. As invited 
speaker, he presented "PET 
as a biomarker in early can- 
cer treatment trials" at the 
City of Hope Comprehensive 
Cancer Center's 2nd Develop- 
mental Cancer Therapeutics/ 
Phase 1 Retreat, Pasadena, 
California, April 4. 
Michael Welch, PhD, 
professor of radiology, of 
chemistry, and of molecular 
biology and pharmacology, 
as invited speaker, presented 
"Functional imaging micro 
PET" at the City of Hope 
Comprehensive Cancer 
Center's 2nd Developmental 
Cancer Therapeutics/Phase 1 





On April 28, Debra 
Gervais, MD, associate 
professor of radiology, 
Harvard Medical 
School; director, Inter- 
ventional Abdominal 
Imaging, Massachusetts 
General Hospital, Boston, presented the Fifteenth Annual Hyman R. Senturia Lec- 
ture. She spoke on "Percutaneous ablation of hepatic malignancies: current status 
and future directions." 
Michael Darcy, MD, thief, Intervention^ Radiology, presented Gervais with a commemorative plaque. 
In this section ofFYI, only 
those faculty and staff who 
have Department of Radiol- 
ogy appointments are listed. 




San Diego, California 
March 7-12, 2009 
FEATURED SYMPOSIUM 
Michael Darcy, MD, "TIPS 
too long"; "SIR Foundation 
and SIR: the big picture." 
VEIN CASE-BASED REVIEW 
Suresh Vedantham, MD, 
"Cases 4-6." 
CATEGORICAL COURSES 
Michael Darcy, MD, "Porto- 
mesenteric venous thrombol- 
ysis—Ho w-I-do-it." 
Suresh Vedantham, MD, 
"The ATTRACT trial and the 
big picture on DVT." 
SCIENTIFIC SESSION 
Seung Kwon Kim, MD, 
"Clinical efficacy of peri- 
toneal ports for management 
of intractable ascites using 
ports designed for venous 
access." 
SOCIETY FOR PEDIATRIC 
RADIOLOGY 
52nd Annual Meeting and 
Postgraduate Course 
Carlsbad, California 
April 21-25, 2009 
Tejaswini Deshmukh, MD; 
Prakash Masand, MD; 
Robert McKinstry, MD, 
PhD, "MR imaging features 
of the malformations of 
cortical development in 
children." 
Geetika Khanna, MD, 
"Evidence based imaging of 
scoliosis." 
FOCAL SPOT, SPRING 2009 
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SYMPOSIA 
Continued from page 31 
William McAllister, MD, 
"Osteoprotegerin (OPG) defi- 
ciency mimicked by a novel 
15-base pair tandem duplica- 
tion in TNFRSF11A encoding 
RANK: merging the juvenile 
Paget's disease and expansile 
skeletal hyperphosphatasia 
phenotypes"; C.1250>G, 
p.N417S is a common Ameri- 
can TNSALP mutation 
involved in all clinical forms 




109"' Annual Meeting 
Boston, Massachusetts 
April 26-May 1,2009 
REVIEW COURSES 
Sanjeev Bhalla, MD, 
Course director, "Approach 
to diagnosis: a case-based 
imaging review." 
Sanjeev Bhalla, MD, 
"Cardiovascular imaging: 
plain film correlates of car- 
diovascular disease." 
Sanjeev Bhalla, MD, "CTA 
of the thorax: pulmonary 
thromboembolic disease, 
arterial and venous malfor- 
mations, acute aortic syn- 
dromes and postoperative 
evaluation of the aorta." 
Cylen Javidan-Nejad, MD, 
"Cardiovascular imaging: 
chest pain." 
Christine Menias, MD, 
moderator/'Genitourinary/ 
OB/GYN (pelvis) imaging 
papers." 
Alumni News 
Within a two-month period, 
Bruce McClennan, MD, former 
chief of Mallinckrodt Institute's 
Abdominal Imaging section, 
received two Gold Medal 
awards: the first from the Soci- 
ety of Uroradiology, the other 
from the American Roentgen 
Ray Society (ARRS). He is a 
professor of radiology at Yale 
University and a former chair of 
Yale's Department of Diagnos- 
tic Radiology. 
John Crowe, MD, 2008-2009 ARRS president, and (left) McClennan at the Gold Medal Award ceremony at the Society's 
109th Annual Meeting in Boston. 
Christine Menias, MD, 
"Gastrointestinal imaging: 
esophagus, stomach, small 
bowel." 
Christine Menias, MD, 
"Acute intestinal ischemia 
and bleeding." 
Pamela Woodard, MD, 
moderator, "Cardiopul- 
monary imaging papers." 
Pamela Woodard, MD, 
keynote, "Cardiac imaging: 
2009 update." 
SCIENTIFIC SESSIONS 
Cylen Javidan-Nejad, MD, 
"Truths and myths of CT- 
guided thoracic biopsies: fac- 
tors affecting complications." 
Cylen Javidan-Nejad, MD; 
Thomas Pilgram, PhD, 
"CT-guided thoracic biopsies: 
a five-year retrospective study 
of outcomes." 
EXHIBITS 
Kartikeya Kantawala, MD; 
Kathryn Robinson, MD; 
Nirvikar Dahiya, MD; 
William Middleton, MD; 
Christine Menias, MD, 
"Liver involvement in heredi- 
tary hemorrhagic telangiec- 
tasia: a multimodality 
approach using CT, MR and 
color Doppler sonography." 
Kartikeya Kantawala, MD; 
Nirvikar Dahiya, MD; 
Kathryn Robinson, MD; 
William Middleton, MD; 
Sharlene Teefey, MD, 
"Virtual cystoscopy using 
three-dimensional ultra- 
sound: a new dimension in 
the evaluation of urinary 
bladder pathologies." 
Christine Menias, MD, 
"Recent imaging and 
interpretation advances 
in diagnostic workup of 
ovarian cystic lesions." 
Editor's Note: On page 5 of the Winter 2008/2009 
Focal Spot, Volume 39, Number 3, a Certificate of 
Merit notation should have been shown for this poster 
presentation: Geetika Khanna, MD; Takashi Sato; Polly 
Ferguson, MD, "Chronic recurrent multifocal 
osteomyelitis: a pictorial review." 
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BJC  INSTITUTE OF HEALTH 
Construction of the BJC Institute of Health at Washington University is 
nearing its targeted completion date of December 2009. The 700,000 
square-foot building at the southwest corner of Euclid Avenue and Chil- 
dren's Place will serve as home base for Washington University's BioMed 
21 initiative to establish a multidisciplinary research environment for the 
acceleration of scientific discovery into clinical care. 
Photograph by Kimberly Kama. 
An artist's rendering of the completed project. 
Printing 
Swift Print Communications 
Focal Spot magazine is distrib- 
uted three times annually. 
www.mir.wusti.edu 
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